Related Party Transactions	9 Months Ended
Sep. 30, 2022
Related Party Transactions [Abstract]
Related Party Transactions	16. Related party transactions Orbital As described in Note 8, the Company has significant influence over, but does not control, Orbital through its noncontrolling representation on Orbital's board of directors and the Company’s equity interest in Orbital. The Company and Orbital are also parties to a collaboration and license agreement and have multiple common board members. The Company has a 31.5% equity interest in Orbital as of September 30, 2022. Verve The Company and Verve are parties to a collaboration and license agreement and had a common board member through the first half of 2022. Prior to Verve’s initial public offering in June 2021, the Company owned both common and preferred shares of Verve and valued such investment based on the cost of the equity securities adjusted for any observable market transactions. Following Verve’s initial public offering, and the conversion of the preferred stock to common stock and a stock split, the equity securities have a readily determinable fair value and the Company owned 546,970 shares of Verve's common stock, the value of which is included in marketable securities in the condensed consolidated balance sheet. The Company recorded the investment at fair value as of September 30, 2022, which resulted in the recognition of other income of $10.4 million and other expense of $1.4 million for the three and nine months ended September 30, 2022, respectively. The Company recorded other expense of $4.9 million and other income of $22.0 million for the three and nine months ended September 30, 2021, respectively related to the changes in fair value of Verve's common stock. The fair value of this investment as of September 30, 2022 is $18.8 million. The Company purchased certain materials from Verve amounting to $0.4 million, which are recorded as research and development expenses within the accompanying condensed consolidated statements of operations and other comprehensive loss, for the three and nine months ended September 30, 2022. The Company purchased $0.2 million of materials from Verve during the nine months ended September 30, 2021. In October 2021, the Company entered into an agreement pursuant to which Verve subleased 12,000 square feet of the Company’s existing office and laboratory space for a term of one year which began in December 2021. Verve is expected to pay approximately $1.4 million in rental payments over the term of the sublease, as well as its proportionate costs for the landlord’s operating expense, insurance, property taxes, and utilities. The Company recorded $0.3 million and $1.0 million of sublease income related to this sublease within the accompanying consolidated statements of operations and other comprehensive loss for the three and nine months ended September 30, 2022, respectively. Prime Medicine The Company and Prime Medicine are parties to the Prime Agreement and have a common founder and had a common board member through the first half of 2022. Additionally, in September 2019, in connection with the Prime Agreement, the Company executed a letter agreement, as amended, to provide certain interim management and startup services to Prime Medicine through March 2021. Prime Medicine was obligated to reimburse the Company’s out-of-pocket costs incurred in connection with performing these services and, beginning in October 2020 and ending in March 2021, paid the Company a $30.0 thousand monthly service fee. There were no interim management and startup services provided to Prime Medicine during the three and nine months ended September 30, 2022. Founders The Company made payments of $0.1 million and $0.3 million to its three founder shareholders for scientific consulting and other expenses for each of the three and nine months ended September 30, 2022 and 2021.

Related Party Transactions

9 Months Ended

Sep. 30, 2022

16. Related party transactions

Orbital

As described in Note 8, the Company has significant influence over, but does not control, Orbital through its noncontrolling representation on Orbital's board of directors and the Company’s equity interest in Orbital. The Company and Orbital are also parties to a collaboration and license agreement and have multiple common board members. The Company has a 31.5% equity interest in Orbital as of September 30, 2022.

Verve

The Company and Verve are parties to a collaboration and license agreement and had a common board member through the first half of 2022.

Prior to Verve’s initial public offering in June 2021, the Company owned both common and preferred shares of Verve and valued such investment based on the cost of the equity securities adjusted for any observable market transactions. Following Verve’s initial public offering, and the conversion of the preferred stock to common stock and a stock split, the equity securities have a readily determinable fair value and the Company owned 546,970 shares of Verve's common stock, the value of which is included in marketable securities in the condensed consolidated balance sheet. The Company recorded the investment at fair value as of September 30, 2022, which resulted in the recognition of other income of $10.4 million and other expense of $1.4 million for the three and nine months ended September 30, 2022, respectively. The Company recorded other expense of $4.9 million and other income of $22.0 million for the three and nine months ended September 30, 2021, respectively related to the changes in fair value of Verve's common stock. The fair value of this investment as of September 30, 2022 is $18.8 million.

The Company purchased certain materials from Verve amounting to $0.4 million, which are recorded as research and development expenses within the accompanying condensed consolidated statements of operations and other comprehensive loss, for the three and nine months ended September 30, 2022. The Company purchased $0.2 million of materials from Verve during the nine months ended September 30, 2021.

In October 2021, the Company entered into an agreement pursuant to which Verve subleased 12,000 square feet of the Company’s existing office and laboratory space for a term of one year which began in December 2021. Verve is expected to pay approximately $1.4 million in rental payments over the term of the sublease, as well as its proportionate costs for the landlord’s operating expense, insurance, property taxes, and utilities. The Company recorded $0.3 million and $1.0 million of sublease income related to this sublease within the accompanying consolidated statements of operations and other comprehensive loss for the three and nine months ended September 30, 2022, respectively.

Prime Medicine

The Company and Prime Medicine are parties to the Prime Agreement and have a common founder and had a common board member through the first half of 2022.

Additionally, in September 2019, in connection with the Prime Agreement, the Company executed a letter agreement, as amended, to provide certain interim management and startup services to Prime Medicine through March 2021. Prime Medicine was obligated to reimburse the Company’s out-of-pocket costs incurred in connection with performing these services and, beginning in October 2020 and ending in March 2021, paid the Company a $30.0 thousand monthly service fee. There were no interim management and startup services provided to Prime Medicine during the three and nine months ended September 30, 2022.

Founders

The Company made payments of $0.1 million and $0.3 million to its three founder shareholders for scientific consulting and other expenses for each of the three and nine months ended September 30, 2022 and 2021.